ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study (UK 92480)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00878943
Recruitment Status : No longer available
First Posted : April 9, 2009
Last Update Posted : January 2, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

April 8, 2009
April 9, 2009
January 2, 2018
 
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo. This protocol provides mechanism for patients who have clinical deterioration on other PAH approved therapies to have access to sildenafil prior to marketing authorization in India.
Not Provided
Expanded Access
Drug: Sildenafil citrate
20 mg tablet to be taken thrice daily for 1 year
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT00878943
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017